Extrait

To obtain proof of principle that omalizumab is of therapeutic benefit to non-atopic asthmatics. Primary Efficacy Parameters Change in pre-bronchodilator FEV1 after 12 weeks of treatment with omalizumab (b) during anti-asthma therapy reduction phase (subsequent 8 weeks of study): The primary outcome measure will be disease exacerbation, defined as a need for rescue oral corticosteroid medication for worsening of symptoms and/or deterioration in lung function,

Critère d'inclusion

• Asthma

Liens

• euctr
• ictrp